Incyte Corporation

INCY · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Ro Khanna D · HOUSE · CA	−$259K – $371K −$409K – $573K today 45 filings · last May 15, 2026
Ed Whitfield R · HOUSE · KY	$1K – $15K $2K – $37K today 1 filing · last Sep 22, 2014
Shelley Moore Capito R · SENATE · WV	−$14K – $14K −$27K – $12K today 2 filings · last Nov 12, 2018
Gilbert Ray Cisneros, Jr. D · HOUSE · CA	−$14K – $14K −$18K – $18K today 2 filings · last Dec 22, 2020

Recent transactions

Trades from Apr 3, 2018 – May 15, 2026

Politician	Type	Filed after	Amount
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	8 days Mar 30, 2026 → Apr 7, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	28 days Mar 10, 2026 → Apr 7, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	8 days Jan 29, 2026 → Feb 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	22 days May 19, 2025 → Jun 10, 2025	≥$1K
Robert Bresnahan R · HOUSE · PA-8	Sell	16 days May 15, 2025 → May 31, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	15 days Feb 19, 2025 → Mar 6, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	20 days Jan 17, 2025 → Feb 6, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	20 days Nov 15, 2024 → Dec 5, 2024	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	35 days Aug 2, 2024 → Sep 6, 2024	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

881

13F shares

204.6M

Total invested

$23.2B

Ownership

102.6%

New positions

123

Closed positions

Increased positions

487

Reduced positions

276

Put/Call ratio

0.56

Holder	Reported	Shares	Value	Δ Qtr
BAKER BROS. ADVISORS LP	8/14/2026	30.8M	$3.5B	+0.06%
BLACKROCK, INC.	8/7/2026	18M	$2.0B	−4.98%
DODGE & COX	8/13/2026	12M	$1.4B	−2.41%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	11M	$1.2B	+0.86%
STATE STREET CORP	9/22/2026	9.7M	$1.1B	+0.84%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	7.8M	$883.2M	+0.41%
AQR CAPITAL MANAGEMENT LLC	8/14/2026	5.3M	$603.2M	−8.39%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	4.8M	$536.5M	+1.01%
LSV ASSET MANAGEMENT	8/6/2026	4.1M	$467.5M	+5.20%
INVESCO LTD.	8/14/2026	4.1M	$462.6M	+5.42%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	3.6M	$405.3M	+9.47%
RENAISSANCE TECHNOLOGIES LLC	8/13/2026	3.5M	$398.1M	−3.82%
MORGAN STANLEY	8/13/2026	2.9M	$334.2M	+3.44%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	2.7M	$311.2M	−3.03%
ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V.	7/21/2026	2.4M	$276.8M	−2.89%
GOLDMAN SACHS GROUP INC	8/14/2026	2.3M	$261.4M	−1.93%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	2.3M	$258.6M	+15.45%
TWO SIGMA INVESTMENTS, LP	8/14/2026	2M	$227.1M	+381.72%
NORTHERN TRUST CORP	8/13/2026	1.8M	$199.7M	−4.74%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	1.7M	$191.9M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	1.7M	$191.9M	−2.12%
ACADIAN ASSET MANAGEMENT LLC	8/13/2026	1.7M	$188.7M	−12.41%
LEGAL & GENERAL GROUP PLC	8/14/2026	1.6M	$182.1M	+4.07%
FIRST TRUST ADVISORS LP	8/11/2026	1.6M	$180.0M	+5.81%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	1.5M	$171.0M	−2.09%

Insider transactions

Insider	Type	Transacted	Price	Date
Clancy Paul J	A-AWARD	203	$121.35	Sep 30
Baker Bros. Advisors Lp	A-AWARD	322	—	Sep 30
Baker Bros. Advisors Lp	A-AWARD	322	—	Sep 30
Harrigan Edmund	A-AWARD	206	$121.35	Sep 30
Gardner David H	F-INKIND	920	$126.93	Sep 22
Cagnoni Pablo J	S-SALE	14K	$120.49	Sep 15
Cagnoni Pablo J	S-SALE	9.2K	$120.50	Sep 15
Cagnoni Pablo J	M-EXEMPT	9.2K	$71.93	Sep 15
Cagnoni Pablo J	M-EXEMPT	6.5K	$64.25	Sep 15
Cagnoni Pablo J	M-EXEMPT	4.6K	$61.18	Sep 15

Analyst consensus

Buy44 analysts

Bearish · 1 · Hold · 20 · Bullish · 23

Earnings history

	EPS	Estimate
Q3 2024	$1.07	$1.12	Miss
Q4 2024	$1.43	$1.57	Miss
Q1 2025	$1.16	$1.01	Beat
Q2 2025	$1.57	$1.39	Beat
Q3 2025	$2.26	$1.66	Beat
Q4 2025	$1.80	$1.90	Miss
Q1 2026	$1.81	$1.34	Beat
Q2 2026	$3.09	$2.15	Beat

Peers

Company overview

IPO dateNov 4, 1993

CEOWilliam J. Meury

Employees2,844

SectorHealthcare

IndustryBiotechnology

CountryUS

ExchangeNASDAQ Global Select

Websitewww.incyte.com

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.